Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, not yet licensed by the MHRA or EMA, with Phase 2 data showing substantial weight reduction over 48 weeks
doi: 10.1172/JCI78085 13 TheofilopoulosANKonoDHBaccalaR
Back to Journals Journal of Inflammation Research Volume 17 Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors Authors Rahim K, Shan M, Ul Haq I, Nawaz MN , Maryam S , Alturki MS, Al Khzem AH , Metwally K, Cavalu S, Alqifari SF , Yahya G Received 18 October 2023 Accepted for publication 9 March 2024 Published 23 March 2024 Volume 2024:17 Pages 18971917 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Adam Bachstetter Kashif Rahim, 1 Muhammad Shan, 2 Ihtisham Ul Haq, 3 5 Muhammad Naveed Nawaz, 2 Sajida Maryam, 3, 4 Mansour S Alturki, 6 Abdulaziz H Al Khzem, 6 Kamel Metwally, 7 Simona Cavalu, 8 Saleh F Alqifari, 9 Galal Yahya 10 1 School of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, Peoples Republic of China
Storage Store the lyophilized vial at 20C, desiccated and protected from light
[4] Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review NIH
